News
CMMB
1.670
0.00%
0.000
Chemomab files Form 3 for CEO and director Adi Mor George beneficial ownership
Reuters · 15h ago
Chemomab Therapeutics director Neil Cohen files initial beneficial ownership statement
Reuters · 15h ago
Chemomab files Form 3 for CFO Fatal Sigal’s initial beneficial ownership stake
Reuters · 15h ago
Chemomab files Form 3 as director Alan Moses reports beneficial ownership
Reuters · 15h ago
Chemomab files Form 3 for Chief Development Officer John Lawler
Reuters · 15h ago
Weekly Report: what happened at CMMB last week (0330-0403)?
Weekly Report · 5d ago
Chemomab files Form 3 for director Jill Quigley’s beneficial ownership statement
Reuters · 03/31 20:06
Weekly Report: what happened at CMMB last week (0323-0327)?
Weekly Report · 03/30 09:08
Weekly Report: what happened at CMMB last week (0316-0320)?
Weekly Report · 03/23 09:08
Analysts Offer Insights on Healthcare Companies: Knight Therapeutics (OtherKHTRF) and Chemomab Therapeutics (CMMB)
TipRanks · 03/22 14:20
Chemomab Therapeutics Sets April 28, 2026 Shareholder Meeting to Vote on Capital Increase and Governance Matters
TipRanks · 03/20 20:27
Maxim Group Remains a Buy on Chemomab Therapeutics (CMMB)
TipRanks · 03/20 13:35
Chemomab Therapeutics reports Q4 results
Seeking Alpha · 03/19 18:39
Chemomab Sets Single-Phase 3 Path With FDA After Strong 2025 Nebokitug Data
TipRanks · 03/19 12:37
Chemomab Therapeutics Q4 EPS $(0.24) Beats $(0.40) Estimate
Benzinga · 03/19 12:27
Chemomab Therapeutics sees cash runway through 1Q27
TipRanks · 03/19 12:11
Israel's Chemomab Q4 net loss narrows on lower R&D spend
Reuters · 03/19 12:09
Chemomab Therapeutics reports FY25 EPS (1c) vs. (4c) last year
TipRanks · 03/19 12:05
Chemomab FY 2025 net loss fell 35.5% to USD 9 million
Reuters · 03/19 12:04
CHEMOMAB THERAPEUTICS: EVALUATING ADDITIONAL THERAPEUTIC INDICATIONS WHERE NEBOKITUG HAS GENERATED ROBUST PRECLINICAL EFFICACY SIGNALS
Reuters · 03/19 12:00
More
Webull provides a variety of real-time CMMB stock news. You can receive the latest news about Chemomab Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About CMMB
Chemomab Therapeutics Ltd (formerly known as Anchiano Therapeutics Ltd) is a Israel-based clinical-stage biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.